Roots Analysis has done a detailed study on “Cell and Gene Therapy CROs Market, 2022-2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- More than 105 CROs claim to provide a wide range of preclinical and clinical services for the development of advanced therapy medicinal products.
- The current market landscape features the presence of established and emerging players, majority of the service providers offer research and analytical services for both cell and gene therapies at different scales of operation.
- Around 1,330 cell and gene therapy focused clinical trials have been registered across the globe; most of the trials are focused on evaluating therapy candidates for the treatment of various oncological indications
- In pursuit of a competitive edge and to eventually establish themselves as one-stop shops, stakeholders have actively entered into mutually beneficial partnerships
- We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings
- Our proprietary analysis highlights several potential acquisition partners for cell and gene therapy service providers across different geographies
- Our proprietary total cost of ownership model provides an informed estimate of direct and indirect expenses for setting up a contract research facility in different regions, over a span of 20 years
- The market is expected to grow at a CAGR of over 21% in the coming decade; the opportunity is likely to be well distributed across areas of expertise, therapeutic areas, scales of operation and key geographical regions
Table of Contents
PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
- EXECUTIVE SUMMARY
2.1. Chapter Overview
- INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Contract Research Organizations (CROs)
3.2.1. Evolution of CROs
3.2.2. Modern CROs and Prevalent Outsourcing Trends
3.3. Type of Services Offered by CROs
3.4. Classification of CROs
3.5. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
3.6. Advantages of Outsourcing Operations to CROs
3.7. Risks Associated with Outsourcing to CROs
3.8. Future Perspectives
- GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Cell and Gene Therapy Research
4.3. Guiding Models of Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Models
4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach
4.5. Selecting a CRO Partner
4.5.1 Key Considerations while Outsourcing Cell and Gene Therapy-related Operations
4.6. Role of CROs in Drug Development
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services
4.7. Concluding Remarks
- MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Scale of Operation
5.2.5. Analysis by Area of Expertise
5.2.6. Analysis by Preclinical Services
5.2.6.1 Analysis by Number of Preclinical Services
5.2.6.2. Analysis by Type of Preclinical Service(s) Offered
5.2.7. Analysis by Clinical Services
5.2.7.1. Analysis by Number of Clinical Services
5.2.7.2. Analysis by Type of Clinical Service(s) Offered
5.2.8. Analysis by Type of Regulatory Service(s) Offered
5.2.9. Analysis by Type of General Support Service(s) Offered
- COMPANY PROFILES
6.1. Chapter Overview
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Allucent (Formerly Known as CATO SMS)
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook
6.2.3. Charles River Laboratories
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Service Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Creative Biolabs
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Recent Developments and Future Outlook
6.2.5. IQVIA
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.2.6. Medpace
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Service Portfolio
6.2.6.4. Recent Developments and Future Outlook
6.2.7. PPD
6.2.7.1. Company Overview
6.2.7.2. Financial Information
6.2.7.3. Service Portfolio
6.2.7.4. Recent Developments and Future Outlook
6.2.8. Precision for Medicine
6.2.8.1. Company Overview
6.2.8.2. Service Portfolio
6.2.8.3. Recent Developments and Future Outlook
6.2.9. QPS
6.2.9.1. Company Overview
6.2.9.2. Service Portfolio
6.2.9.3. Recent Developments and Future Outlook
6.3. Players based in Europe
6.3.1. Accelera
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Evotec
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. ICON
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Syneos Health
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.4. Players based in Asia-Pacific
6.4.1.1. CMIC Group
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Service Portfolio
6.4.1.5. Recent Developments and Future Outlook
6.4.2. Labcorp
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Service Portfolio
6.4.2.4. Recent Developments and Future Outlook
- COMPETITIVE BENCHMARKING
7.1. Chapter Overview
7.2. Assumptions and Key Methodology
7.3. Competitive Benchmarking by Region
7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
7.3.7. Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
7.4. Concluding Remarks
- PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell and Gene Therapy CROs: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partnership and Company Size
8.3.5. Analysis by Area of Expertise
8.3.6. Analysis by Year of Partnership and Area of Expertise
8.3.7. Analysis by Type of Partnership and Area of Expertise
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Region
8.3.9.1. Intracontinental and Intercontinental Deals
8.3.9.2. Local and International Deals
- MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
9.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
9.3.2. Analysis by Type of Agreement
9.3.3. Analysis by Region
9.3.3.1. Mergers and Acquisitions: Continent-wise Distribution
9.3.3.2. Mergers and Acquisitions: Country-wise Distribution
9.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
9.3.5. Analysis by Key Value Drivers
9.3.6. Analysis by Year of Acquisition and Key Value Drivers
9.3.7. Key Acquisitions: Deal Multiples
- KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scoring Criteria and Key Assumptions
10.3. Scope and Methodology
10.4. Potential Strategic Acquisition Targets Amongst Small Players
10.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players
- LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scoring Criteria and Key Assumptions
11.3. Scope and Methodology
11.4. Key Potential Strategic Partners for Cell Therapy CROs
11.4.1. Likely Partner Opportunities for Dendritic Cell Therapy CROs
11.4.2. Likely Partner Opportunities for NK Cell Therapy CROs
11.4.3. Likely Partner Opportunities for Stem Cell Therapy CROs
11.4.4. Likely Partner Opportunities for T-Cell Therapy CROs
- LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scoring Criteria and Key Assumptions
12.3. Scope and Methodology
12.4. Key Potential Strategic Partners for Gene Therapy CROs
12.4.1. Likely Partner Opportunities in North America
12.4.2. Likely Partner Opportunities in Europe
12.4.3. Likely Partner Opportunities in Asia-Pacific and RoW
- CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Trial Phase
13.3.4. Analysis by Type of Sponsor
13.3.5. Analysis by Geography
13.3.6. Analysis by Trial Status and Geography
13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Phase
13.4.3. Analysis by Trial Status and Geography
13.5. Gene Therapies: Analysis by Number of Clinical Trials
13.5.1. Analysis by Trial Registration Year
13.5.2. Analysis by Trial Status
13.5.3. Analysis by Trial Phase
13.5.4. Analysis by Therapeutic Area
13.5.5. Analysis by Type of Sponsor
13.5.6. Analysis by Geography
13.5.7. Analysis by Trial Status and Geography
13.6. Gene Therapies: Analysis by Enrolled Patient Population
13.6.1. Analysis by Trial Registration Year
13.6.2. Analysis by Trial Phase
13.6.3. Analysis by Therapeutic Area
13.6.4. Analysis by Trial Status and Geography
- TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT RESEARCH ORGANIZATIONS
14.1 Chapter Overview
14.2. Key Parameters
14.3. Assumptions and Methodology
14.4 Sample dataset for the estimation of total cost of ownership
14.4.1 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20
14.4.2. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX, Y0: Distribution of CAPEX (USD Million)
14.4.3. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis By OPEX, Y1-Y20
- MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Global Cell and Gene Therapy CROs Market, 2022-2035
15.3.1. Cell and Gene Therapy CROs Market: Analysis by Area of Expertise
15.3.1.1. Cell Therapy CROs Market, 2022-2035
15.3.1.2. Gene Therapy CROs Market, 2022-2035
15.3.2. Cell and Gene Therapy CROs Market: Analysis by Scale of Operation
15.3.2.1. Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035
15.3.2.2. Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035
15.3.2.3. Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035
15.3.3. Cell and Gene Therapy CROs Market: Analysis by Therapeutic Area, 2022-2035
15.3.3.1. Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035
15.3.3.2. Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035
15.3.3.3. Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035
15.3.3.4. Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035
15.3.3.5. Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035
15.3.3.6. Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035
15.3.3.7. Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035
15.3.3.8. Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035
15.3.3.9. Cell and Gene Therapy CROs Market for Ophthalmic Disorders, 2022-2035
15.3.3.10. Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035
15.3.4. Cell and Gene Therapy CROs Market: Analysis by Geography, 2022-2035
15.3.4.1. Cell and Gene Therapy CROs Market in North America, 2022-2035
15.3.4.2. Cell and Gene Therapy CROs Market in Europe, 2022-2035
15.3.4.3. Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035
15.3.4.4. Cell and Gene Therapy CROs Market in Latin America, 2022-2035
15.3.4.5. Cell and Gene Therapy CROs Market in MENA, 2022-2035
- SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
- CONCLUSION
17.1. Chapter Overview
- INTERVIEW AND SURVEY TRANSCRIPTS
18.1. Chapter Overview
18.2. CATO SMS
18.2.1. Company Snapshot
18.2.2. Survey Transcript: Jessica Bliven, Director, Marketing and Sales
18.3. Changhai Hospital, Second Military Medical University
18.3.1. University Snapshot
18.3.2. Survey Transcript: Xian-Bao Zhan, Professor of Medicine, Director, Department of Oncology
18.4. University of Colorado
18.4.1. University Snapshot
18.4.2. Survey Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
- APPENDIX 1: TABULATED DATA
- APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html
You may also be interested in the following titles:
Cell Therapy Manufacturing Market
You may also like to learn what our experts are sharing in Roots educational series:
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek